224 related articles for article (PubMed ID: 15095572)
1. [ACE inhibitors in the treatment of ventricular dysfunction caused by cardiotoxic cytostatics].
Mladosievicová B
Ceska Slov Farm; 2004 Mar; 53(2):55-60. PubMed ID: 15095572
[TBL] [Abstract][Full Text] [Related]
2. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
3. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
4. Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.
Silber JH; Cnaan A; Clark BJ; Paridon SM; Chin AJ; Rychik J; Hogarty AN; Cohen MI; Barber G; Rutkowsky M; Kimball TR; Delaat C; Steinherz LJ; Zhao H; Tartaglione MR
Am Heart J; 2001 Oct; 142(4):577-85. PubMed ID: 11579345
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors in left ventricular dysfunction.
Linn WD
Pharmacotherapy; 1996; 16(2 Pt 2):50S-58S. PubMed ID: 8668606
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
8. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
[TBL] [Abstract][Full Text] [Related]
9. Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials.
Greenberg BH
J Card Fail; 2002 Dec; 8(6 Suppl):S486-90. PubMed ID: 12555162
[TBL] [Abstract][Full Text] [Related]
10. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
Cardinale D; Colombo A; Sandri MT; Lamantia G; Colombo N; Civelli M; Martinelli G; Veglia F; Fiorentini C; Cipolla CM
Circulation; 2006 Dec; 114(23):2474-81. PubMed ID: 17101852
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
12. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
Phillips CO; Kashani A; Ko DK; Francis G; Krumholz HM
Arch Intern Med; 2007 Oct; 167(18):1930-6. PubMed ID: 17923591
[TBL] [Abstract][Full Text] [Related]
14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
15. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Makkar KM; Sanoski CA; Spinler SA
Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction--a meta-analysis.
Abdulla J; Pogue J; Abildstrøm SZ; Køber L; Christensen E; Pfeffer MA; Yusuf S; Torp-Pedersen C
Eur J Heart Fail; 2006 Jan; 8(1):90-6. PubMed ID: 16054435
[TBL] [Abstract][Full Text] [Related]
17. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
[TBL] [Abstract][Full Text] [Related]
18. A hard look at angiotensin receptor blockers in heart failure.
Gring CN; Francis GS
J Am Coll Cardiol; 2004 Nov; 44(9):1841-6. PubMed ID: 15519017
[TBL] [Abstract][Full Text] [Related]
19. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
Masoudi FA; Rathore SS; Wang Y; Havranek EP; Curtis JP; Foody JM; Krumholz HM
Circulation; 2004 Aug; 110(6):724-31. PubMed ID: 15289383
[TBL] [Abstract][Full Text] [Related]
20. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
